Dalteparin
- Generic Name
- Dalteparin
- Brand Names
- Fragmin
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- S79O08V79F
- Background
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more pre...
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk f...
- Associated Conditions
- Cardiovascular Events, Clotting, Deep Vein Thrombosis, Symptomatic Venous Thromboembolism, Venous Thromboembolism
- Associated Therapies
- -
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
- Conditions
- Interventions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00006083
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 141
- Registration Number
- NCT00003674
- Locations
- ๐บ๐ธ
CCOP - Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธCCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
๐บ๐ธCCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT00028678
- Locations
- ๐บ๐ธ
CCOP - Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธWest Michigan Cancer Center, Kalamazoo, Michigan, United States
๐บ๐ธCCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Gary Morrow
- Target Recruit Count
- 400
- Registration Number
- NCT00031837
- Locations
- ๐บ๐ธ
MBCCOP - Gulf Coast, Mobile, Alabama, United States
๐บ๐ธMBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธCCOP - Central Illinois, Decatur, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.